Solvonis’ SVN-015 Accepted into NIDA Program for Addiction Treatment

Solvonis Therapeutics ( (GB:SVNS) ) just unveiled an announcement.

Solvonis Therapeutics has announced that its AI-discovered compound, SVN-015, has been accepted into the US National Institute on Drug Abuse’s Addiction Treatment Discovery Program for methamphetamine and cocaine addiction. This acceptance marks a significant milestone for Solvonis, as it expands its research into stimulant addictions, which currently have no approved drug treatments. The program will initially involve preclinical safety studies, potentially leading to efficacy studies and further NIH funding. This development could enhance Solvonis’ position in the CNS disorder treatment market and provide new opportunities for addressing critical unmet needs in addiction treatment.

More about Solvonis Therapeutics

Solvonis Therapeutics plc is an emerging biopharmaceutical company based in London and listed on the London Stock Exchange. The company focuses on developing novel small-molecule therapeutics for high-burden central nervous system (CNS) disorders, including addiction, psychiatry, and neurology. Solvonis is advancing a pipeline of repurposed and novel compounds, with lead programs addressing Alcohol Use Disorder (AUD) and Post-Traumatic Stress Disorder (PTSD).

Average Trading Volume: 54,742,193

Technical Sentiment Signal: Sell

Current Market Cap: £17.02M

For an in-depth examination of SVNS stock, go to TipRanks’ Overview page.